EN DE
Watch Kiora Pharmaceuticals Inc for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Kiora Pharmaceuticals Inc (KPRX) fair value: what the stock is really worth

As of Nov 20, 2026: fair value (intrinsic value) of Kiora Pharmaceuticals Inc stock $0.713, price $0.72, that is 1.0% below the price, quality 26 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently applies, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US49721T3095

KP Kiora Pharmaceuticals Inc logo Thin data Nov 22, 2026

Kiora Pharmaceuticals Inc

KPRX · US

Rising price, but the stock is already about fairly priced and weak company: meets 1 of 3 rules.

Follow free in the weekly email
Rising price (uptrend) 
Fair value $0.713 · Fairly valued 
Mixed Growth (revenue 5y +42.9 %/yr in USD) 
Mixed vs. peers (3/6) 
Quality 26/100 
Negative free cash flow 
Narrow moat 8/100 · thin data
Thin data 
Estimate
Watch Kiora Pharmaceuticals Inc for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$810.00 $0.72 Fair Value $0.713 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 22, 2026.

How to read this chart

60‑month range $0.72 – $810.00 · fair‑value band $0.535 – $0.891 · the $0.72 price screens above the $0.713 fair value. As of Nov 22, 2026.

Follow Kiora Pharmaceuticals in your weekly email

Every Wednesday you see whether Kiora Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases.

Show moreShow less

Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.

The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis.

It has a strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia.

The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Stock analysis

Kiora Pharmaceuticals Inc (KPRX) currently trades at $0.72, while our estimate is $0.713, so the stock looks roughly fairly valued today (gap 1.0%).

Show more

Valuation

None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.535 (bear) to $0.891 (bull), the price of $0.72 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Kiora Pharmaceuticals Inc reported revenue of $0 in FY2025 versus $12.1K in FY2021. Reported net income was −$10.8M in FY2025.

Key figures

Market cap $4.4M Micro · P/S ratio 3.19 · EPS (TTM) $-2.72 · Return on equity −67.7% · Return on assets (EBIT) −51.0% (5-year average) · Operating margin −890% · Revenue (TTM) $1.0M · Free cash flow −$10.1M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 75% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at −1%, KPRX screens cheaper than that median.

Fair Value

Bear $0.535 Fair Value $0.713 Bull $0.891
Price $0.72 · Downside -1.0%
Estimate. None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 26/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 0
Are margins and returns getting better?
Cashflow 28
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 47
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 14
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 20, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 32/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+998.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+42.9%
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+48.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−260.6% (2019) → 28.2% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch KPRX, get fair value alerts →

Compare Kiora Pharmaceuticals Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 854 stocks

Beats the industry median on 3/5 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 26 · Bottom 25%
Fair Value upside −1.0% · Top 25%
Profitability
Return on assets −44.7% · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.28× · Cheapest 25%
P/S (12 months) 4.45× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)32 · sector 0
FUTURE (revenue growth)0 · sector 32
PAST (return on equity)0 · sector 0
HEALTH (low debt)–
DIVIDEND (yield)0 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $920.69 $1,275.02 +38% vs KPRX
Vertex Pharmaceuticals Incorporated VRTX $515.02 $566.52 +10% vs KPRX
Samsung Biologics Co 207940 ₩1,355,000 ₩1,490,500 +10% vs KPRX
argenx SE ARGX $925.70 $908.40 −2% vs KPRX
CSL Limited CSL A$197.29 A$188.80 −4% vs KPRX
BeOne Medicines AG 6160 HK$230.80 HK$152.92 −34% vs KPRX
Moderna, Inc MRNA $195.00 $119.97 −38% vs KPRX
Revolution Medicines, Inc RVMD $161.20 $83.14 −48% vs KPRX
Celltrion, Inc 068270 ₩213,000 ₩74,574 −65% vs KPRX
Royalty Pharma plc RPRX $68.45 $19.01 −72% vs KPRX

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Kiora Pharmaceuticals Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Kiora Pharmaceuticals Inc Fair Value". https://www.fairvalue-calculator.com/stock/KPRX

Frequently asked questions

Is Kiora Pharmaceuticals Inc (KPRX) overvalued or undervalued?
As of Nov 22, 2026, our estimate of fair value is $0.713 versus a price of $0.72, about 1% lower (fairly valued).
What is the fair value of KPRX?
Our estimate for Kiora Pharmaceuticals Inc is $0.713 (as of Nov 22, 2026), built from audited fundamentals. The current price: $0.72.
What is the quality score of KPRX?
Kiora Pharmaceuticals Inc has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Kiora Pharmaceuticals Inc (KPRX)?
We do not set a price target; the yardstick is our estimate of $0.713 (as of Nov 22, 2026). Cautious scenario $0.535, optimistic scenario $0.891. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently applies, not an analyst target.
What is the Kiora Pharmaceuticals Inc stock forecast for 2026?
Our estimate puts fair value at $0.713, about 1% lower versus a price of $0.72 (fairly valued). Cautious scenario $0.535, optimistic scenario $0.891. The calculation is refreshed regularly with new filings.
What is the revenue of Kiora Pharmaceuticals Inc (KPRX)?
Kiora Pharmaceuticals Inc reported trailing-twelve-month revenue of about $1.0M (latest available figure, as of Nov 22, 2026).
What is the intrinsic value of Kiora Pharmaceuticals Inc (KPRX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Kiora Pharmaceuticals Inc it is $0.713 per share (as of Nov 22, 2026), against a price of $0.72.
Is Kiora Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Nov 22, 2026, KPRX trades above its calculated fair value: price $0.72, fair value $0.713, a gap of about −1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of KPRX?
No. The price is what the market pays today ($0.72); the fair value is what the company's own numbers justify ($0.713). For Kiora Pharmaceuticals Inc the two are $0.0069 per share apart. That gap is exactly why we show both numbers side by side.
How much is Kiora Pharmaceuticals Inc worth?
The market values Kiora Pharmaceuticals Inc at about $4.4M (market capitalisation, as of Nov 22, 2026). Per share that is $0.72; our models calculate a fair value of $0.713 per share.
What do the bullish and bearish scenarios say about KPRX?
Our models span a range for Kiora Pharmaceuticals Inc: cautious scenario $0.535, base $0.713, optimistic $0.891 per share (as of Nov 22, 2026, price $0.72). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Kiora Pharmaceuticals Inc (KPRX)?
Balance-sheet figures for Kiora Pharmaceuticals Inc (as of Nov 22, 2026): return on equity −67.7%. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is KPRX from its 52-week high?
Kiora Pharmaceuticals Inc trades at $0.72, about 75% below its 52-week high of $2.86 and at the low of $0.72 (as of Nov 20, 2026). Distance from the high says nothing about value: that is what the fair value of $0.713 is for.
Which stocks are comparable to Kiora Pharmaceuticals Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Kiora Pharmaceuticals Inc stock attractive at the current price?
The data as of Nov 22, 2026: price $0.72, calculated fair value $0.713 (−1%), Quality Score 26/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 10.1% above its aggregate fair value. Kiora Pharmaceuticals Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Kiora Pharmaceuticals Inc (KPRX)?
The closing price on Nov 20, 2026 was $0.72. Our estimate is $0.713, about 1% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Kiora Pharmaceuticals Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Kiora Pharmaceuticals Inc

How large is the market capitalisation of Kiora Pharmaceuticals Inc (KPRX)?
The market capitalisation of Kiora Pharmaceuticals Inc is $4.4M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Kiora Pharmaceuticals Inc (KPRX)?
The price-to-sales ratio of Kiora Pharmaceuticals Inc is 3.19 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Kiora Pharmaceuticals Inc (KPRX)?
Earnings per share at Kiora Pharmaceuticals Inc are $-2.72. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Kiora Pharmaceuticals Inc (KPRX)?
The return on equity (ROE) of Kiora Pharmaceuticals Inc is −67.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Kiora Pharmaceuticals Inc (KPRX)?
On an EBIT basis the return on assets of Kiora Pharmaceuticals Inc is −51.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Kiora Pharmaceuticals Inc (KPRX)?
The operating margin of Kiora Pharmaceuticals Inc is −890% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Kiora Pharmaceuticals Inc (KPRX) generate?
The free cash flow of Kiora Pharmaceuticals Inc is −$10.1M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Kiora Pharmaceuticals Inc (KPRX) hold?
Kiora Pharmaceuticals Inc holds more cash than debt, $8.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Kiora Pharmaceuticals Inc in the live analysis

One click puts Kiora Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.